Eledon Pharmaceuticals, Inc. Board of Directors

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Dr. Steven N. Perrin Ph.D.

Dr. Steven N. Perrin Ph.D.

President, Chief Scientific Officer & Non Independent Director

Mr. John Herberger

Mr. John Herberger

Vice President of Technical Operations

Mr. Paul Sean Little

Mr. Paul Sean Little

Chief Financial Officer

Dr. David Hovland Ph.D.

Dr. David Hovland Ph.D.

Chief Regulatory Officer

Mr. Bryan E. Smith J.D.

Mr. Bryan E. Smith J.D.

General Counsel, Corporate Secretary & Chief Compliance Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.